Outcome after neoadjuvant chemotherapy in Asian breast cancer patients
详细信息 查看全文
- 作者：Li Yan Lim ; Hui Miao ; Joline S. J. Lim ; Soo Chin Lee ; Nirmala Bhoo-Pathy ; Cheng Har Yip ; Nur Aishah B. M. Taib ; Patrick Chan ; Ern Yu Tan ; Swee Ho Lim ; Geok Hoon Lim ; Evan Woo ; Yia Swam Tan ; Jung Ah Lee ; Mabel Wong ; Puay Hoon Tan ; Kong Wee Ong ; Fuh Yong Wong ; Yoon Sim Yap and Mikael Hartman
- 刊名：Cancer Medicine
- 出版年：2017
- 出版时间：January 2017
- 年：2017
- 卷：6
- 期：1
- 页码：173-185
- 全文大小：246K
- ISSN：2045-7634
文摘
We aim to identify clinicopathologic predictors for response to neoadjuvant chemotherapy and to evaluate the prognostic value of pathologic complete response (pCR) on survival in Asia. This study included 915 breast cancer patients who underwent neoadjuvant chemotherapy at five public hospitals in Singapore and Malaysia. pCR following neoadjuvant chemotherapy was defined as 1) no residual invasive tumor cells in the breast (ypT0/is) and 2) no residual invasive tumor cells in the breast and axillary lymph nodes (ypT0/is ypN0). Association between pCR and clinicopathologic characteristics and treatment were evaluated using chi-square test and multivariable logistic regression. Kaplan–Meier analysis and log-rank test, stratified by other prognostic factors, were conducted to compare overall survival between patients who achieved pCR and patients who did not. Overall, 4.4% of nonmetastatic patients received neoadjuvant chemotherapy. The median age of preoperatively treated patients was 50 years. pCR rates were 18.1% (pCR ypT0/is) and 14.4% (pCR ypT0/is ypN0), respectively. pCR rate was the highest among women who had higher grade, smaller size, estrogen receptor negative, human epidermal growth factor receptor 2-positive disease or receiving taxane-based neoadjuvant chemotherapy. Patients who achieved pCR had better overall survival than those who did not. In subgroup analysis, the survival advantage was only significant among women with estrogen receptor-negative tumors. Patients with poor prognostic profile are more likely to achieve pCR and particularly when receiving taxane-containing chemotherapy. pCR is a significant prognostic factor for overall survival especially in estrogen receptor-negative breast cancers.